Tuesday, 26 August 2025
  
Login

Australia's most trusted
source of pharma news

Tuesday, 26 August 2025
News

Pharma pulls drug over pricing

 Posted 25 August 2025 PM

After its first-in-class treatment for chronic hypothyroidism was again knocked back by the PBAC, Specialised Therapeutics (ST) has announced it will not make the drug available to Australian patients, blaming the "current impasse on pricing".

ST CEO Carlo Montagner told Pharma in Focus that despite offering Yorvipath at the "lowest price in the world by some margin" the PBAC was still not satisfied.

To see the whole article, please login

Popular

Pharma pulls drug over pricing
July PBAC winners and losers
Hottest jobs in pharma named
AZ hosts Girls to Graduates event
Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (2)

Sales & Customer Relations (11)

Clinical & Medical, R&D (9)

Regulatory, Pharmacovigilance & QA (5)

Other (13)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2025 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home